Natalie Callander is a Hematology physician affiliated with University of Wisconsin Carbone Cancer Center. OpenAlex indexes 445 publications with 16,232 citations (h-index 61); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Highland Ave
Madison, WI 53792
Telephone
608-265-1700Provider last certified this registry record 21 Jan 2021.
Clinical trials
- Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Sponsor: ECOG-ACRIN Cancer Research Group
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Cellectar Biosciences, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TAIHO ONCOLOGY, INC.Program year20259 payments
- AstraZeneca Pharmaceuticals LPProgram year20257 payments
- Janssen Biotech, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
24.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor24.3%Acyclovir100%Part D≥67 patientsNervous system
20%Opioid Agonist9.8%Oxycodone Hcl33%Morphine Sulfate Er32%Oxycontin27%Morphine Sulfate8%Part D<11 patientsBenzodiazepine3.3%Lorazepam74%Alprazolam26%Part D<11 patients+ 6 more classes in this area
Cancer & immunology
19.5%Thalidomide Analog16.8%Revlimid50%Lenalidomide31%Pomalyst19%Part D≥20 patientsBCL-2 Inhibitor1.5%Venclexta100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
New England Journal of Medicine
2023 - Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023 - NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Journal of the National Comprehensive Cancer Network
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Glenn Liu, MD
University of Wisconsin Carbone Cancer Center
Hongtao Liu
University of Wisconsin Carbone Cancer Center
Susan Payne, MD
University of Wisconsin Carbone Cancer Center
Vaishalee Kenkre, MD
University of Wisconsin Carbone Cancer Center
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”